أعرض في EDS

Supplemental Table 3 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

التفاصيل البيبلوغرافية
العنوان:	Supplemental Table 3 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
المؤلفون:	Josep Tabernero, Irene Braña, Maria Alsina, Jorge D. Gallo, Brett E. Houk, Lixin Han, Kristen J. Pierce, Gary Borzillo, Robert Millham, Susan S. Pandya, Eunice L. Kwak, James Spicer, Johanna Bendell, Julian R. Molina, Katherine M. Bell-McGuinn, Geoffrey I. Shapiro
بيانات النشر:	American Association for Cancer Research (AACR), 2023.
سنة النشر:	2023
الوصف:	Supplemental Table 3. Cycle 1 results of the pharmacokinetic analysis of PF-05212384 administered at the maximum tolerated dose
DOI:	10.1158/1078-0432.22456169.v1
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f79cf89011c4a0210cc955c3f4cde0 https://doi.org/10.1158/1078-0432.22456169.v1
Rights:	OPEN
رقم الانضمام:	edsair.doi.dedup.....72f79cf89011c4a0210cc955c3f4cde0
قاعدة البيانات:	OpenAIRE

الوصف
DOI:	10.1158/1078-0432.22456169.v1